Display options
Cite
Tremlett H, Zhu F, Arnold D, et al. The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Ann Clin Transl Neurol. 2021;8(12):2252-2269doi: 10.1002/acn3.51476.
Tremlett, H., Zhu, F., Arnold, D., Bar-Or, A., Bernstein, C. N., Bonner, C., Forbes, J. D., Graham, M., Hart, J., Knox, N. C., Marrie, R. A., Mirza, A. I., O'Mahony, J., Van Domselaar, G., Yeh, E. A., Zhao, Y., Banwell, B., Waubant, E. (2021). The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Annals of clinical and translational neurology, 8(12), 2252-2269. https://doi.org/10.1002/acn3.51476
Tremlett, Helen, et al. "The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes." Annals of clinical and translational neurology vol. 8,12 (2021): 2252-2269. doi: https://doi.org/10.1002/acn3.51476
Tremlett H, Zhu F, Arnold D, Bar-Or A, Bernstein CN, Bonner C, Forbes JD, Graham M, Hart J, Knox NC, Marrie RA, Mirza AI, O'Mahony J, Van Domselaar G, Yeh EA, Zhao Y, Banwell B, Waubant E. The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Ann Clin Transl Neurol. 2021 Dec;8(12):2252-2269. doi: 10.1002/acn3.51476. Epub 2021 Dec 09. PMID: 34889081.
Copy Download .nbib Format: NLM
Share it on

Ann Clin Transl Neurol. 2021 Dec;8(12):2252-2269. doi: 10.1002/acn3.51476. Epub 2021 Dec 09.

The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes.

Annals of clinical and translational neurology

Helen Tremlett, Feng Zhu, Douglas Arnold, Amit Bar-Or, Charles N Bernstein, Christine Bonner, Jessica D Forbes, Morag Graham, Janace Hart, Natalie C Knox, Ruth Ann Marrie, Ali I Mirza, Julia O'Mahony, Gary Van Domselaar, E Ann Yeh, Yinshan Zhao, Brenda Banwell, Emmanuelle Waubant,

Affiliations

  1. Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, V6T 1Z3, Canada.
  2. The Montreal Neurological Institute, McGill University, Montreal, Quebec, H3A 2B4, Canada.
  3. Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perleman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
  4. Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, R3E 3P4, Canada.
  5. National Microbiology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, R3E 3R2, Canada.
  6. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.
  7. Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Manitoba, R3E 0J9, Canada.
  8. Department of Neurology, University of California San Francisco, San Francisco, California, 94158, USA.
  9. Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Manitoba, R3A 1R9, Canada.
  10. The Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada.
  11. Division of Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.

PMID: 34889081 DOI: 10.1002/acn3.51476

Abstract

OBJECTIVE: To examine the gut microbiota in individuals with and without pediatric-onset multiple sclerosis (MS).

METHODS: We compared stool-derived microbiota of Canadian Pediatric Demyelinating Disease Network study participants ≤21 years old, with MS (disease-modifying drug [DMD] exposed and naïve) or monophasic acquired demyelinating syndrome [monoADS] (symptom onset <18 years), and unaffected controls. All were ≥30 days without antibiotics or corticosteroids. V4 region 16S RNA gene-derived amplicon sequence variants (Illumina MiSeq) were assessed using negative binomial regression and network analyses; rate ratios were age- and sex-adjusted (aRR).

RESULTS: Thirty-two MS, 41 monoADS (symptom onset [mean] = 14.0 and 6.9 years) and 36 control participants were included; 75%/56%/58% were female, with mean ages at stool sample = 16.5/13.8/15.1 years, respectively. Nine MS cases (28%) were DMD-naïve. Although microbiota diversity (alpha, beta) did not differ between participants (p > 0.1), taxa-level and gut community networks did. MS (vs. monoADS) exhibited > fourfold higher relative abundance of the superphylum Patescibacteria (aRR = 4.2;95%CI:1.6-11.2, p = 0.004, Q = 0.01), and lower abundances of short-chain fatty acid (SCFA)-producing Lachnospiraceae (Anaerosporobacter) and Ruminococcaceae (p, Q < 0.05). DMD-naïve MS cases were depleted for Clostridiales vadin-BB60 (unnamed species) versus either DMD-exposed, controls (p, Q < 0.01), or monoADS (p = 0.001, Q = 0.06) and exhibited altered community connectedness (p < 10

INTERPRETATION: Gut microbiota community structure, function and connectivity, and not just individual taxa, are of likely importance in MS.

© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

References

  1. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. https://doi.org/10.1371/journal.pbio.1002533 - PubMed
  2. Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB, Waubant E. The gut microbiome in human neurological disease: a review. Ann Neurol. 2017;81(3):369-382. https://doi.org/10.1002/ana.24901 - PubMed
  3. Pröbstel AK, Zhou X, Baumann R, et al. Gut microbiota-specific IgA(+) B cells traffic to the CNS in active multiple sclerosis. Sci Immunol. 2020;5(53):eabc7191. https://doi.org/10.1126/sciimmunol.abc7191 - PubMed
  4. Berer K, Gerdes LA, Cekanaviciute E, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA. 2017;114(40):10719-10724. https://doi.org/10.1073/pnas.1711233114 - PubMed
  5. Cekanaviciute E, Yoo BB, Runia TF, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci USA. 2017;114(40):10713-10718. https://doi.org/10.1073/pnas.1711235114 - PubMed
  6. Mirza A, Forbes JD, Zhu F, et al. The multiple sclerosis gut microbiota: a systematic review. Mult Scler Relat Disord. 2020;37:101427. https://doi.org/10.1016/j.msard.2019.101427 - PubMed
  7. Tremlett H, Marrie RA. The multiple sclerosis prodrome: emerging evidence, challenges, and opportunities. Mult Scler. 2021;27(1):6-12. https://doi.org/10.1177/1352458520914844 - PubMed
  8. Jackson MA, Verdi S, Maxan M-E, et al. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat Commun. 2018;9(1):2655. https://doi.org/10.1038/s41467-018-05184-7 - PubMed
  9. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65:57-62. https://doi.org/10.1136/gutjnl-2015-309618 - PubMed
  10. Fadda G, Brown RA, Longoni G, et al. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health. 2018;2(3):191-204. https://doi.org/10.1016/s2352-4642(18)30026-9 - PubMed
  11. Hunsberger M, O'Malley J, Block T, Norris JC. Relative validation of Block Kids Food Screener for dietary assessment in children and adolescents. Maternal Child Nutr. 2015;11(2):260-270. https://doi.org/10.1111/j.1740-8709.2012.00446.x - PubMed
  12. Caporaso JG, Lauber CL, Walters WA, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012;6(8):1621-1624. https://doi.org/10.1038/ismej.2012.8 - PubMed
  13. Amir A, McDonald D, Navas-Molina JA, et al. Deblur rapidly resolves single-nucleotide community sequence patterns. mSystems. 2017;2(2):e00191-16. https://doi.org/10.1128/mSystems.00191-16 - PubMed
  14. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852-857. https://doi.org/10.1038/s41587-019-0209-9 - PubMed
  15. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71(12):8228-8235. https://doi.org/10.1128/AEM.71.12.8228-8235.2005 - PubMed
  16. Kurtz ZD, Muller CL, Miraldi ER, Littman DR, Blaser MJ, Bonneau RA. Sparse and compositionally robust inference of microbial ecological networks. PLoS Comput Biol. 2015;11(5):e1004226. https://doi.org/10.1371/journal.pcbi.1004226 - PubMed
  17. Layeghifard M, Hwang DM, Guttman DS. Disentangling interactions in the microbiome: a network perspective. Trends Microbiol. 2017;25(3):217-228. https://doi.org/10.1016/j.tim.2016.11.008 - PubMed
  18. Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol. 2020;38(6):685-688. https://doi.org/10.1038/s41587-020-0548-6 - PubMed
  19. Caspi R, Billington R, Fulcher CA, et al. The MetaCyc database of metabolic pathways and enzymes. Nucleic Acids Res. 2017;46(D1):D633-D639. https://doi.org/10.1093/nar/gkx935 - PubMed
  20. Rhee JJ, Sampson L, Cho E, Hughes MD, Hu FB, Willett WC. Comparison of methods to account for implausible reporting of energy intake in epidemiologic studies. Am J Epidemiol. 2015;181(4):225-233. https://doi.org/10.1093/aje/kwu308 - PubMed
  21. Azary S, Schreiner T, Graves J, et al. Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018;89(1):28-33. https://doi.org/10.1136/jnnp-2017-315936 - PubMed
  22. Murtagh F, Legendre P. Ward’s hierarchical agglomerative clustering method: which algorithms implement ward’s criterion? J Classif. 2014;31(3):274-295. https://doi.org/10.1007/s00357-014-9161-z - PubMed
  23. Nourbakhsh B, Bhargava P, Tremlett H, Hart J, Graves J, Waubant E. Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. Ann Clin Transl Neurol. 2018;5(10):1211-1221. https://doi.org/10.1002/acn3.637 - PubMed
  24. Tremlett H, Fadrosh DW, Faruqi AA, et al. Gut microbiota in early pediatric multiple sclerosis: a case-control study. Eur J Neurol. 2016;23(8):1308-1321. https://doi.org/10.1111/ene.13026 - PubMed
  25. Miyake S, Kim S, Suda W, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLoS One. 2015;10(9):e0137429. https://doi.org/10.1371/journal.pone.0137429 - PubMed
  26. Chen J, Chia N, Kalari KR, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:28484. https://doi.org/10.1038/srep28484 - PubMed
  27. Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7:12015. https://doi.org/10.1038/ncomms12015 - PubMed
  28. Calderón-Pérez L, Gosalbes MJ, Yuste S, et al. Gut metagenomic and short chain fatty acids signature in hypertension: a cross-sectional study. Sci Rep. 2020;10(1):6436. https://doi.org/10.1038/s41598-020-63475-w - PubMed
  29. Hu X, Ouyang S, Xie Y, Gong Z, Du J. Characterizing the gut microbiota in patients with chronic kidney disease. Postgrad Med. 2020;132(6):495-505. https://doi.org/10.1080/00325481.2020.1744335 - PubMed
  30. Waters JL, Ley RE. The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health. BMC Biol. 2019;17(1):83. https://doi.org/10.1186/s12915-019-0699-4 - PubMed
  31. Mancabelli L, Milani C, Lugli GA, et al. Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. FEMS Microbiol Ecol. 2017;93(12). https://doi.org/10.1093/femsec/fix153 - PubMed
  32. Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The controversial role of human gut lachnospiraceae. Microorganisms. 2020;8(4):573. https://doi.org/10.3390/microorganisms8040573 - PubMed
  33. Ventura RE, Iizumi T, Battaglia T, et al. Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course. Sci Rep. 2019;9(1):16396. https://doi.org/10.1038/s41598-019-52894-z - PubMed
  34. Katz Sand I, Zhu Y, Ntranos A, et al. Disease-modifying therapies alter gut microbial composition in MS. Neurol Neuroimmunol Neuroinflamm. 2019;6(1):e517. https://doi.org/10.1212/NXI.0000000000000517 - PubMed
  35. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019;16(8):461-478. https://doi.org/10.1038/s41575-019-0157-3 - PubMed
  36. Nimmagadda VKC, Makar TK, Chandrasekaran K, et al. SIRT1 and NAD+ precursors: therapeutic targets in multiple sclerosis a review. J Neuroimmunol. 2017;304:29-34. https://doi.org/10.1016/j.jneuroim.2016.07.007 - PubMed
  37. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8(11):647-656. https://doi.org/10.1038/nrneurol.2012.168 - PubMed
  38. Dopkins N, Nagarkatti PS, Nagarkatti M. The role of gut microbiome and associated metabolome in the regulation of neuroinflammation in multiple sclerosis and its implications in attenuating chronic inflammation in other inflammatory and autoimmune disorders. Immunology. 2018;154(2):178-185. https://doi.org/10.1111/imm.12903 - PubMed
  39. Duscha A, Gisevius B, Hirschberg S, et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell. 2020;180(6):1067-1080.e16. https://doi.org/10.1016/j.cell.2020.02.035 - PubMed
  40. Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9(2):216-237. https://doi.org/10.1007/s13238-017-0451-1 - PubMed
  41. MetaCyc: Caspi et al. Nucleic Acids Research 46(D1):D633-D639 2018. Page generated by Pathway Tools version 24.0 (software by SRI International) on Mon Sep 21, 2020, BIOCYC14A. 2020 - PubMed
  42. Nijland PG, Molenaar RJ, van der Pol SM, et al. Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions. Acta Neuropathol Commun. 2015;3(1):79. https://doi.org/10.1186/s40478-015-0261-8 - PubMed
  43. Giacalone G, Clarelli F, Osiceanu AM, et al. Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. Mult Scler. 2015;21(11):1431-1442. https://doi.org/10.1177/1352458514564590 - PubMed
  44. Lacorte E, Gervasi G, Bacigalupo I, Vanacore N, Raucci U, Parisi P. A systematic review of the microbiome in children with neurodevelopmental disorders. Systematic review. Front Neurol. 2019;10:727. https://doi.org/10.3389/fneur.2019.00727 - PubMed
  45. Zhou X, Singh S, Baumann R, et al. Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis. Mult Scler. 2021;27(3):366-379. https://doi.org/10.1177/1352458520924594 - PubMed
  46. The World Bank data catalog. Fertility rates, 2018. Accessed 20-May-2021. https://datacatalog.worldbank.org/dataset/world-development-indicators - PubMed
  47. Schendel DE, Parner E. Sibling comparisons and confounding in autism epidemiological studies. JAMA Psychiatry. 2016;73(3):302-303. - PubMed
  48. Marrie RA, Cohen J, Stuve O, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler. 2015;21(3):263-281. https://doi.org/10.1177/1352458514564491 - PubMed
  49. Knight R, Vrbanac A, Taylor BC, et al. Best practices for analysing microbiomes. Nat Rev Microbiol. 2018;16(7):410-422. https://doi.org/10.1038/s41579-018-0029-9 - PubMed
  50. Callahan BJ, McMurdie PJ, Holmes SP. Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. ISME J. 2017;11(12):2639-2643. https://doi.org/10.1038/ismej.2017.119 - PubMed

Publication Types

Grant support